Local News

Becoming “One Less”

November 29, 2007

By Whitney Shaw

In 2006 a vaccine came onto the scene promising to do what hasn’t been done before: prevent cancer. While the Gardisil vaccine gives hope to many women who could otherwise fall prey to cervical cancer, but even as it is becoming more popular, the shot is not being received openly in many circles.

Gardisil is a vaccine recommended for women between the ages of 9 and 26 as protection against the Human Papilloma Virus (HPV), a virus that can manifest itself in many ways, including cervical cancer. It is estimated that 20 million people in the United States carry the virus, and that “50 percent of sexually active people will catch HPV during their lifetime,” according to Merck & Co., the shot’s manufacturer. The vaccine’s campaign encourages women to become “One Less” victim of cervical cancer.

In most secular circles, getting vaccinated may seem like an obvious choice. However, students and other young women who are choosing to remain abstinent until marriage are finding the decision more difficult, considering that HPV is sexually transmitted. And some worry that the vaccine may encourage promiscuity since the chances of negative consequences are greatly reduced.

“Even if you’re not going to have sex until you’re married, you can’t protect yourself against rape or sexual assault. It’s just a good precaution,” said MBU senior Laura Hildebrand.

Another drawback to getting the vaccine is cost. There are three shots in the series, and each is very expensive. Many insurance companies do not cover the cost of the shot, and the price discourages many young women from getting it. “I was told $165 per shot at the Visiting Nurses Association. It’s expensive, but when you think that it’s going to prevent cancer, it’s worth it,” said Hildebrand.

#   #   #